Cryoport — Third Quarter 2026 Earnings Summary

Cryoport reported third-quarter 2026 revenue of $50.2 million, representing a 14% year-over-year increase driven by growth in commercial cell and gene therapy services and BioStorage/BioServices. The company supported a record 788 global clinical trials and 23 commercially approved therapies as of September 30, 2026, while achieving a positive adjusted EBITDA of $1.1 million for the quarter. Reflecting this momentum, Cryoport raised its full-year 2026 revenue guidance to a range of $197 million to $199 million. The company held $393.1 million in cash, cash equivalents, and short-term investments at the end of the quarter.